4.7 Article

Identification of Key Players for Colorectal Cancer Metastasis by iTRAQ Quantitative Proteomics Profiling of Isogenic SW480 and SW620 Cell Lines

Journal

JOURNAL OF PROTEOME RESEARCH
Volume 10, Issue 10, Pages 4373-4387

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/pr2005617

Keywords

colorectal cancer (CRC); metastasis; iTRAQ proteomics; SW480; SW620; beta-catenin; calcyclin binding protein (CacyBP); whole cell proteome

Funding

  1. National University of Singapore (NUS), Faculty of Science [R-154-000-401-133]
  2. NUS

Ask authors/readers for more resources

This study compared the whole cell proteome profiles of two isogenic colorectal cancer (CRC) cell lines (primary SW480 cell line and its lymph node metastatic variant SW620), as an in vitro metastatic model, to gain an insight into the molecular events of CRC metastasis. Using iTRAQ(isobaric tags for relative and absolute quantitation) based shotgun proteornics approach, we identified 1140 unique proteins, out of which 147 were found to be significantly altered in the metastatic cell. Ingenuity pathway analysis with those significantly altered proteins, revealed cellular organization and assembly as the top-ranked altered biological function. Differential expression pattern of 6 candidate proteins were validated by Western blot. Among these, the low expression level of beta-catenin combined with the up-regulation of CacyBP (Calcyclin binding Protein), a beta-catenin degrading protein, in the metastatic cell provided a rational guide for the downstream functional assays. The relative expression pattern of these two proteins was further validated in three other CRC cells by Western blot and quantitative immunofluorescence studies. Overexpression of CacyBP in three different primary CRC cell lines showed significant reduction in adhesion characteristics as well as cellular beta-catenin level as confirmed by our experiments, indicating the possible involvement of CacyBP in CRC metastasis. In short, this study demonstrates successful application of a quantitative proteomics approach to identify novel key players for CRC metastasis, which may serve as biomarkers and/or drug targets to improve CRC therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available